3DEACON CF, HOLST JJ. Dipeptidyl peptidase Ⅳ inhibitors: A promising new therapeutic approach for the management of type 2 diabetes[ J ].Int J Biochem Cell Biol, 2006,38 (5-6) : 831 - 844.
4DEACON CF. Circulalion and degradation of GIP and GLP-1 [ J ] . Horm Metab Res , 2004, 36(11-12):761 -765.
5RASMUSEEN HB,BRANNER S, WIBERG FC, et al. Crystal structure of truman dipeptidyl peptidase Ⅳ/CD26 in complex with a subetratc analog[J]. Nat Struct Biol,2003,10(1) :19-25.
6LAMBEIR AM, DURINXC C, SCHARPE S, et al. Dipeptidyl peptidase Ⅳ from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP Ⅳ [J]. Crit Rev Clin Lab Sci,2003, 40(3) :209 -294.
7AHREN B, LANDIRR OM, JANSSON PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glyocmia, sustains insulin levels,and reduces glucagon levels in type 2 diabetes[J]. J Clin Endocrinal Metab ,2004,89 ( 5 ) :2078 - 2084.
8POSPISILIK JA, MASTIN J, DOTY T, et al. Dipeptidyl Peptidase Ⅳ inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptcuotocirr induced diabetic rat [ J ]. Diabetes, 2003, 52(3) : 741 -750.
9CONARDLO SL, LI Z, RONAN J, et al. Mice lacking dieptidyl peptidase Ⅳ are protected against obesity and insulin resistance [J]. Proc Natl Acad Sci USA,2003,100(11) :6825 -6830.
10DOOSEOP K, WANG LP, BECONI M, et al. (2R)-4-Oxo-4- [ 3- (Trifluoromethy]) -5,6-dihydro [ 1,2,4 ] triazolo - [ 4,3-a pyrazin-7 ( 8 H ) -yl]-1 -( 2,4,5 -trifluorophenyl ) butan-2-amine : a potent, orally active dipeptidyl peptidase Ⅳ inhibitor for the treatment of type 2 diabetes [ J ]. J Med Chem, 2005, 48 ( 1 ) : 141 - 151.
6Nathan DM, Buse JB, Davidson MB, et aL Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association forthe Study of Diabetes. Diabetes Care, 2009, 32(1): 193-203.
7Stratton IM, Adler AI, Neff HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BM], 2000, 321(4): 405-412.
8The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabe- tes mellitus. N Engl J Ailed, 1993, 329(5): 977-986.
9Setter SM, lltz JL, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus:a clinical review with a focus on dual therapy. ClinTher, 2003, 25(2): 2991-3026.
10Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosigli- tazone/metform in fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patientswith uncontrolled type 2 diabetes. Diabetes Obes Metab, 2006, 8(6): 650-660.
